Dr. James M. Lipton
Biography & Research Background
James M. Lipton, PhD, is a pioneering researcher affiliated with Zengen Inc. and the University of Texas. Lipton is the lead inventor who established that the anti-inflammatory and antipyretic activities of the larger α-MSH hormone reside specifically in its C-terminal tripeptide sequence, KPV. He demonstrated that KPV exerts efficacy across a broad range of concentrations, including physiological picomolar ranges, and holds multiple patents for its use in treating dermatological disorders, uro-genital conditions, and systemic inflammation. James M. Lipton is being referenced as one of the leading scientists involved in the research and development of KPV. In no way is this doctor/scientist endorsing or advocating the purchase, sale, or use of this product for any reason. There is no affiliation or relationship, implied or otherwise, between Pure US Peptide and this doctor.
External Profiles
Authored Research Profiles (1)
Dr. James M. Lipton is referenced as a leading researcher in the following peptide research profiles on Pure U.S. Peptides:
Dr. James M. Lipton is being referenced as one of the leading scientists involved in the research and development of the peptides listed above. In no way is this doctor/scientist endorsing or advocating the purchase, sale, or use of any product for any reason. There is no affiliation or relationship, implied or otherwise, between Pure U.S. Peptides and this researcher. The purpose of citing the researcher is to acknowledge, recognize, and credit the exhaustive research and development efforts conducted by the scientists studying these peptides.